Immunovia AB

Immunovia AB is a diagnostic company focused on revolutionizing blood-based diagnostics for early detection of pancreatic cancer. Their mission is to increase survival rates for patients by developing and commercializing simple blood tests that detect proteins and antibodies indicating the presence of pancreatic cancer in high-risk individuals. Immunovia is committed to collaborating with healthcare providers, experts, and patient advocacy groups to make these tests widely accessible.

The company's focus on the US, the world's largest market for pancreatic cancer detection, highlights their ambition. They estimate that 1.8 million individuals in the US could benefit from annual surveillance testing, demonstrating a significant market potential for their innovative diagnostic solutions. Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm, indicating their commitment to transparency and accountability within the financial markets.

Immunovia AB is a Swedish diagnostic company dedicated to revolutionizing blood-based diagnostics and increasing survival rates for pancreatic cancer patients through early detection. They focus on developing and commercializing simple blood tests that detect proteins and antibodies, identifying high-risk individuals who have developed pancreatic cancer. Immunovia actively collaborates with healthcare providers, leading experts, and patient advocacy groups to ensure their tests are accessible to those at increased risk for this devastating disease.

Immunovia fosters a culture that emphasizes ethical conduct, open communication, and the importance of collaboration. The company values its employees' contributions and encourages them to raise concerns or issues through its whistleblower program. This commitment to transparency and employee well-being contributes to a healthy and open work environment.